Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (ISAV).
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 May 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ISAV
- 24 Nov 2016 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
- 24 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2018.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology